Cavion - About the company
Cavion is an acquired company based in Charlottesville (United States), founded in 2005. It operates as a Targeted therapies for neuropathic pain and brain cancer. Cavion has raised $49M in funding from Lilly Ventures and Novartis Venture Fund. The company has 2846 active competitors, including 977 funded and 709 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.
Company Details
Cavion Pharma, formerly known as Tau Therapeutics, was formed in 2014 when Tau Therapeutics acquired Xdynia. It develops small molecule drugs for neurological disorders by targeting the Cav3 molecule in the T-type calcium channels. Its lead candidates are in phase 3 clinical trials for neuropathic pain management. Another candidate mibefradil is in phase II trials for recurrent glioblastoma multiforme, a type of brain cancer.
- Website
- cavionpharma.com
- Social
Key Metrics
Founded Year
2005
Location
Charlottesville, United States
Stage
Acquired
Total Funding
$49M in 9 rounds
Latest Funding Round
Investors
Ranked
807th among 2846 active competitors
Similar Companies
Exit Details
Acquired by Jazz Pharmaceuticals (Aug 12, 2019)
Cavion's acquisition details
Cavion got acquired by Jazz Pharmaceuticals on Aug 12, 2019 at an acquisition amount of $*****.
Click here to take a look at Cavion's acquisition in detail
Sign up to download Cavion's company profile
Cavion's funding and investors
Cavion has raised a total funding of $49M over 9 rounds. Its latest funding round was a Series A round on Jan 12, 2017 for $*****. 3 investors participated in its latest round. Cavion has 5 institutional investors.
Here is the list of recent funding rounds of Cavion:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 12, 2017 | 3936082 | Series A | 3563282 | 2916586 | 5879487 | 9964104 |
Nov 10, 2015 | 4651485 | Series A | 8613435 | 2394557 | 9785486 | 9390968 |
Jun 09, 2014 | 4681055 | Series A | 9694359 | 6211349 | 6348908 | 4311689 |
Access funding benchmarks and valuations. Sign up today!View details of Cavion's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Cavion's Competitors and alternates
Top competitors of Cavion include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Cavion, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 77/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
5th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
807th | Cavion 2005, Charlottesville (United States), Acquired | Targeted therapies for neuropathic pain and brain cancer | $49M | 43/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Cavion's competitors? Click here to see the top ones
Cavion's Investments and acquisitions
Cavion has made no investments or acquisitions yet.
Reports related to Cavion
Here is the latest report on Cavion's sector:
News related to Cavion
Filter this list•
Jazz acquires biotech Cavion for up to $312.5MSeeking Alpha•Aug 12, 2019•Jazz Pharmaceuticals, Cavion, Novartis, Lilly
•
•
•
Cavion to Announce Results of its Phase 2 Essential Tremor Clinical TrialBioSpace•Oct 04, 2018•Cavion
•
•
•
•
First Patient Enrolled in Cavion Multi-Center Phase 2 Clinical Trial in EpilepsyBusiness Wire•Mar 20, 2018•Cavion
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Cavion
Explore our recently published companies
- Saalfo Tech - Mysuru based, 1990 founded, Unfunded company
- Tolia - Thane based, 1979 founded, Unfunded company
- Uvtcpl - India based, Unfunded company
- Diamondexch99 - Unfunded company
- Krishna's Herbal & Ayurveda - Jodhpur based, 2007 founded, Funding Raised company
- Dash - Atlanta based, 2025 founded, Unfunded company
